Recce Pharmaceuticals Secures Patent Protecting Anti-Infectives in Brazil Until 2041
Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.
- Brazilian National Institute grants Family 4 patent for RECCE 327 and RECCE 529
- Patent covers preparation processes and multiple administration methods
- Protection extends to treatment of bacterial and viral infections including superbugs
- Brazilian antibiotics market valued at over AUD 1 billion and growing
- Recce now holds seven Family 4 patents globally with ongoing international filings
Expanding Intellectual Property in a Strategic Market
Recce Pharmaceuticals Limited (ASX:RCE) has achieved a significant intellectual property milestone with the Brazilian National Institute of Industrial Property granting a Family 4 patent for its synthetic anti-infectives, RECCE 327 and RECCE 529. This patent, valid until 2041, safeguards the company’s proprietary processes and therapeutic uses in Brazil, a key market in South America.
Brazil’s antibiotics market is substantial and growing, with revenues reaching approximately AUD 1.09 billion in 2024 and projected to expand to AUD 1.36 billion by 2033. By securing patent protection here, Recce is positioning itself to tap into this expanding market, which is critical given the global urgency to combat antibiotic-resistant infections.
Broad Protection Across Multiple Infection Types and Delivery Methods
The patent covers not only the preparation of Recce’s anti-infectives but also their use in treating a wide spectrum of infections. These include acute bacterial skin infections, diabetic foot infections, burn wounds, lung infections such as ventilator-associated pneumonia, urinary tract infections, gonorrhoea, influenza, and even SARS-CoV-2. The versatility of administration methods; oral, inhalation, transdermal, injection, and topical applications; further underscores the comprehensive nature of this protection.
This breadth of coverage reflects Recce’s innovative approach to addressing antibiotic resistance through synthetic polymers designed to overcome mechanisms that typically render existing antibiotics ineffective. The company’s pipeline includes three patented compounds, with RECCE 327 and RECCE 529 now formally protected in Brazil alongside other major markets including Australia, Canada, China, and Japan.
Strategic Implications and Future Outlook
Recce’s CEO, James Graham, highlighted the importance of this patent as a validation of the company’s platform technology and a critical step in expanding its global reach. The granted patent not only strengthens Recce’s competitive position but also supports its broader mission to tackle the growing threat of antibiotic-resistant superbugs worldwide.
While the announcement does not specify timelines for commercialisation or clinical trial progress within Brazil, the patent grant signals confidence in Recce’s technology and its potential to meet unmet medical needs. Investors and industry watchers will be keen to monitor subsequent regulatory approvals and market entry strategies in this important region.
Bottom Line?
With Brazil’s patent secured, Recce is poised to deepen its impact in the global fight against antibiotic resistance; next steps will reveal how swiftly this translates into market presence.
Questions in the middle?
- What are the timelines for clinical trials and regulatory approvals for Recce’s anti-infectives in Brazil?
- How will Recce navigate competition within the South American antibiotics market?
- What commercial partnerships or strategies will Recce pursue to capitalise on this patent?
